CDKN2A and metastatic melanoma: EM5 was isolated from a stage III lymph node-resected metastatic melanoma that was TP53 wild type, BRAFV600E-mutated and CDKN2 A-deficient (Figure 7d and Supplementary Figure K), thereby passing these criteria.